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Alexandre Lapillonne1, Nitida Pastor2, Weihong Zhuang2 and Deolinda MF Scalabrin2*Abstract
Background: Long chain polyunsaturated fatty acids (LCPUFAs) may influence the immune system. Our objective
was to compare the frequency of common illnesses in infants who received formula with or without added
LCPUFAs.
Methods: In this observational, multi-center, prospective study, infants consumed formula with 17 mg DHA and
34 mg ARA/100 kcal (n = 233) or with no added DHA or ARA (n = 92). Pediatricians recorded respiratory illnesses,
otitis media, eczema, and diarrhea through 1 year of age.
Results: Infants who consumed formula with DHA/ARA had lower incidence of bronchitis/bronchiolitis (P = 0.004),
croup (P = 0.044), nasal congestion (P = 0.001), cough (P = 0.014), and diarrhea requiring medical attention
(P = 0.034). The odds ratio (OR) of having at least one episode of bronchitis/bronchiolitis (0.41, 95% CI 0.24, 0.70;
P = 0.001), croup (0.23, 95% CI 0.05, 0.97; P = 0.045), nasal congestion (0.37, 95% CI 0.20, 0.66; P = 0.001), cough
(0.52, 95% CI 0.32, 0.86; P = 0.011), and diarrhea requiring medical attention (0.51, 95% CI 0.28, 0.92; P = 0.026) was
lower in infants fed DHA/ARA. The OR of an increased number of episodes of bronchitis/bronchiolitis, croup, nasal
congestion, cough, and diarrhea, as well as the hazard ratio for shorter time to first episode of bronchitis/bronchiolitis,
nasal congestion, cough, and diarrhea were also significantly lower in the DHA/ARA group.
Conclusions: In healthy infants, formula with DHA/ARA was associated with lower incidence of common respiratory
symptoms and illnesses, as well as diarrhea.
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Appropriate nutrition during infancy and early childhood
provides critical support to the immune system and may
reduce the incidence of common illnesses during this age
period. Attention has increasingly focused on the potential
role of long-chain polyunsaturated fatty acids (LCPUFAs)
such as docosahexaenoic acid (DHA; 22:6n-3) and arachi-
donic acid (ARA; 20:4n-6) as immunomodulatory nutri-
ents [1]. Infants receive LCPUFAs from dietary sources
including human milk, infant formula with added DHA* Correspondence: deolinda.scalabrin@mjn.com
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article, unless otherwise stated.and ARA, certain types of food rich in LCPUFAs such as
fish, fish oil, and eggs, and endogenously through the con-
version of the precursors alpha-linolenic and linoleic acid.
DHA and ARA are incorporated into cell membranes and
contribute to immune cell activity through a variety of dif-
ferent mechanisms [2]. In previous studies, both preterm
[3] and full-term [4] infants who were fed formula with
DHA and ARA displayed lymphocyte populations, cytokine
production, and immune cell maturation that resembled
those of breastfed infants, suggesting that dietary intake of
DHA and ARA, whether via human milk or infant formula,
contributes to immune development.
Dietary LCPUFAs have been shown to affect the inci-
dence of respiratory illnesses and allergic manifestationstral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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of LCPUFAs in human milk, for example, were associated
with reduced incidence of atopic diseases [6,7], while
maternal supplementation with LCPUFAs during lacta-
tion was associated with a reduction in the incidence
of bronchopulmonary dysplasia and allergic rhinitis in
preterm infants [8]. Additionally, early introduction of
fish has been associated with reduced prevalence of
eczema [9-11], allergic rhinitis [12,13], and recurrent
wheezing [14]. Few studies, however, have specifically
investigated the effects of infant formula with DHA
and ARA on such illnesses. In an observational study
in Spain, infant formula with DHA and ARA was asso-
ciated with a lower incidence of respiratory illnesses
[15]. Based on this observation, we designed the current
study to compare the frequency of common illnesses dur-
ing the first year of life in healthy infants receiving formula
with or without added DHA and ARA. We sought to
confirm our prior results on respiratory illnesses [15], in a
different population of infants, and to extend those re-
sults by tracking the incidence of other common infant
illnesses such as otitis media, diarrhea, and eczema.Methods
Study design
Enrollment for this multicenter, prospective, observational,
open-label study was conducted from January 2008 to April
2009 at 22 pediatric outpatient clinics in France. Inclusion
criteria were: healthy term infants born after 37 weeks
of gestation, singleton, with a birth weight, length, and
head circumference appropriate for gestational age
(≥10th and ≤90th percentile), less than 60 days of age at en-
rollment, and exclusively fed with one of the study formulas
for at least 24 hours before enrollment. Exclusion criterion
was participation in any other clinical trial.
Infants were categorized into one of two study groups
based on the formula they were currently consuming:
 DHA/ARA: infant and follow-on formulas containing
17 mg of DHA/100 kcal and 34 mg of ARA/100 kcal
(Enfamil Premium 1® and Enfamil Premium 2®, Mead
Johnson Nutrition, Evansville, IN, USA) or
 Control: infant and follow-on formulas without
added DHA/ARA (Enfalac® and Enfamil 2®, Mead
Johnson Nutrition, Evansville, IN, USA).
The composition of the formulas in the 2 groups was
similar; the main difference between them was the content
of DHA and ARA. The infants received infant formulas
until approximately 4 months of age (i.e. Enfamil Premium
1® or Enfalac®) and follow-on formulas (Enfamil Premium
2® or Enfamil 2®) from approximately 4 months until
12 months of age. Recommendations with regards to theintroduction of weaning foods were left to the discretion of the
pediatrician.
Each pediatrician participating in this study was esti-
mated to have the capacity to enroll 4–6 eligible in-
fants per month. Participating pediatricians were asked
to enroll eligible infants that were already consuming
one of the pre-determined infant formulas. The choice
of formula was made at the discretion of the parents
before the recruitment. The pediatrician was instructed to
not recommend a formula other than the one already be-
ing used by the participant at the time of enrollment.
Pediatricians followed participants until 12 months of age
at routine visits and any unscheduled visit or telephone call.
Routine visits were at 1 to 2 months (visit 1), 2 to 3 months
(visit 2), and approximately 4 (visit 3), 6 (visit 4), and 12
(visit 5) months of age.
At the initial visit, the pediatrician completed a case
report form including information on the infant’s med-
ical history, family history of allergy, and parents’ socio-
economic background. The case report form provided 7
categories in which to record parents’ professional
information. Among them, “No professional activity”
was the lower level; “Farmers”, “Craftsmen, businessmen,
business owners”, “Intermediate professions”, “Office
employees”, and “Labors” were combined to form an
intermediate level; “Upper level management and higher-
level professions” composed the upper level. Six levels of so-
cioeconomic status were then formed using a combination
of both parents’ socioeconomic status, e.g.: both parents
upper level; one upper level and one intermediate level; etc.
At each visit, anthropometric measurements and occur-
rence of feeding intolerance were recorded, as well as com-
pliance with the study formulas. Respiratory symptoms and
illnesses (nasal congestion, cough, bronchitis/bronchiolitis,
and croup), otitis media, diarrhea, and eczema, as assessed
by the pediatrician, were also recorded. At each visit,
anthropometric variables were recorded and converted
to z-scores based on WHO references [16].
Ethics
This study was conducted according to the guidelines of
the Declaration of Helsinki and all procedures involving
human subjects/patients and handling of medical re-
cords were approved by the appropriate local authorities
[National Board of Physicians (CNOM), the Consultative
Committee on Information Processing in Health Research
(CCTIRS) and the National Commission on Informatics
and Liberties (CNIL)]. All parents were given written in-
formation on the study and their informed verbal consent
was obtained in all cases. Each patient was monitored with
no obligation or constraint; in particular, no follow-up
visit, medical procedure, or additional exam of any sort
was imposed. The participating pediatricians remained
free to choose the medical treatment for each participant’s
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Statistical analysis
Characteristics of the study population, including family
history of eczema, asthma, and bronchiolitis, smoking
in the home, gender and type of feeding (breastfed or
non-breastfed) prior to study formula were analyzed
using Fisher's exact test. Differences in duration of
breastfeeding for those who were breastfed were ana-
lyzed by analysis of variance (ANOVA). Weight, length,
and head circumference at birth were analyzed for males
and females separately by ANOVA. For each type of ill-
ness, the proportion of infants in each group having at
least one episode during the first year of life was com-
pared using Fisher’s exact test.
To adjust for covariates, multiple logistic regression was
used to examine the association between formula type and
illness. For infection-related illnesses or symptoms of illness
(bronchitis/bronchiolitis, nasal congestion, cough, croup,
otitis media, and diarrhea requiring medical attention),
potential covariates included mother’s educational
level, father’s educational level, parents’ socioeconomic
status, smoking in the home, number of people living
in the home, and daycare exposure. Potential covari-
ates for allergy-related illness (eczema) included gen-
der, family allergy history, mother’s educational level,
father’s educational level, parents’ socioeconomic sta-
tus, smoking in the home, number of people living in
the home, and daycare exposure. All potential covari-
ates were retained in a preliminary logistic regression
model and stepwise selection was used to select covari-
ates with significant evidence at an alpha level of 0.05.
The selected covariates were then included in a final
logistic regression model.
Further analyses using an ordinal model examined
the number of episodes of illness or symptom. For the
ordinal analysis of bronchitis/bronchiolitis, cough, and
nasal congestion, the number of episodes was truncated at
3, due to sparse frequency of more than 3 episodes. For
the ordinal analysis of all other illnesses, the number of
episodes was truncated at 2. The same set of covariates
was included in the ordinal model as were used in the
final logistic regression model.
In the multiple regression analysis and the ordinal
analysis, only two covariates reached significance (mother’s
educational level and early daycare exposure) and for only
one outcome (bronchiolitis/bronchitis). A Cox proportional
hazards model was used to examine the time to first
diagnosis of illness during the study period.
All P values reported are based on two-tailed tests. A
P value of < 0.05 was considered statistically significant
for all analyses. Statistical analyses were performed using
SAS® software (version 9.1; SAS Institute, Cary, NC).Results
Participant characteristics
Three hundred and twenty five infants were included
in the study. Infant characteristics at birth were simi-
lar between groups (Table 1) with the exception of
weight (Mean ± SE; Control: 3195 ± 68.3 g, DHA/ARA:
3383 ± 41.4 g; P = 0.02) and length (Control: 48.7 ± 0.3 cm,
DHA/ARA: 49.6 ± 0.2 cm; P = 0.04) of females, which were
significantly lower in the Control group, but these differ-
ences were no longer significant at the time of study enroll-
ment. The number of infants who were reported as being
breastfed at any time prior to study enrollment was signifi-
cantly higher in the control group (n (%); Control: 70
(76%); DHA/ARA 144 (62%); P = 0.02); however, when
feeding type was further broken down into the 3 categories
of non-breastfed, mixed feeding, and exclusively breast-
fed, there was no significant difference in the distribu-
tion between Control and DHA/ARA groups (P = 0.07;
Table 1). The duration (days) of breastfeeding for those
infants who were breastfed was not different in the 2
groups (Mean ± SE; Control: 34 ± 2.3; DHA/ARA: 32 ± 1.5;
P = 0.52). The number of infants with early daycare expos-
ure was higher in the DHA/ARA group, but there was no
difference in late daycare exposure (Table 1).Growth
Group z-scores for females differed for weight-for-
age at visit 4 (approx. 6 months of age) (Mean ± SE;
Control: −0.2 ± 0.1; DHA/ARA: 0.2 ± 0.1; P = 0.015)
and visit 5 (approx. 9 months of age) (Mean ± SE; Control:
0.0 ± 0.1; DHA/ARA: 0.5 ± 0.1; P = 0.005). There were no
significant differences in length- or head circumference-
for-age z-scores for females and in weight-, length-, and
head circumference-for-age z-scores for males at any time
during the study (data not shown).Incidence of illnesses
DHA/ARA consumption was associated with a lower
incidence (n, %) of respiratory illnesses, with a significant
effect on both bronchitis/bronchiolitis (Control: 43 (47%),
DHA/ARA: 68 (29%); P = 0.004) and croup (Control: 5
(5%), DHA/ARA: 3 (1%); P = 0.044) (Figure 1). DHA/ARA
intake was also associated with a lower incidence (n, %)
of symptoms of respiratory illness during the first year of
life, including nasal congestion (Control: 75 (82%), DHA/
ARA: 144 (62%); P = 0.001) and cough (Control: 58 (63%),
DHA/ARA: 110 (47%); P = 0.014).
With regard to other common infant illnesses, DHA/
ARA intake was associated with a lower incidence (n, %) of
diarrhea requiring medical attention (Control: 23, (25%),
DHA/ARA: 34 (15%); P = 0.034), but there was no statisti-
cally significant difference in the incidence of eczema
(Control: 28 (30%), DHA/ARA: 49 (21%); P = 0.083)
Table 1 Characteristics of the study participants
DHA/ARA Control P-value
Study enrollment, n 233 92 —
Study completion, n (%) 204 (88%) 78 (85%) 0.59
Gender (male), n (%) 121 (52%) 51 (55%) 0.62
Birth characteristics
Weight (g), Mean (SE)
Males (DHA/ARA n = 119;
Control n = 51)
3375 (39.1) 3433 (59.7) 0.42
Females (DHA/ARA n = 109;
Control n = 40)
3383 (41.4) 3195 (68.3) 0.02
Length (cm), Mean (SE)
Males 49.9 (0.2) 50.2 (0.3) 0.41
Females 49.6 (0.2) 48.7 (0.3) 0.04
Head circumference (cm),
Mean (SE)
Males 35.0 (0.1) 34.9 (0.2) 0.65
Females 34.6 (0.1) 34.3 (0.2) 0.13
Enrollment characteristics
Age (days) at enrollment
Males 41.3 (1.5) 38.3 (2.3) 0.28
Females 45.6 (1.4) 43.2 (2.4) 0.39
Weight (g), Mean (SE)
Males 4594.9 (75.2) 4524.1 (113.9) 0.61
Females 4566.8 (68.8) 4378.4 (117.0) 0.17
Length (cm), Mean (SE)
Males 55.0 (0.3) 54.7 (0.4) 0.53
Females 54.9 (0.3) 54.3 (0.4) 0.28
Head circumference (cm),
Mean (SE)
Males 38.0 (0.2) 37.7 (0.2) 0.32
Females 37.7 (0.1) 37.4 (0.2) 0.26
Feeding
Ever breastfed, n (%) 144 (62%) 70 (76%) 0.02
Non-breastfed, n (%) 88 (43%) 22 (30%)
Mixed feeding, n (%) 60 (29%) 21 (28%) 0.07
Exclusively breastfed, n (%) 59 (29%) 31 (42%)
Breastfeeding duration (days),
Mean (SE)
32 (1.5) 34 (2.3) 0.52
Family history of allergy, n (%)
Eczema 49 (21%) 19 (21%) 1.00
Asthma 47 (20%) 16 (17%) 0.64
Smoking in home, n (%) 50 (22%) 21 (23%) 0.88
Mother’s educational level, n (%) 0.54
High 64 (28%) 20 (22%)
Intermediate 142 (63%) 60 (67%)
Low 19 (8%) 9 (10%)
Table 1 Characteristics of the study participants
(Continued)
Parents’ socioeconomic level, n (%) 0.80
Both upper 36 (16%) 15 (16%)
One upper/One intermediate 32 (14%) 13 (14%)
One upper/One lower 9 (4%) 1 (1%)
Both intermediate 111 (49%) 46 (51%)
One intermediate/One lower 35 (15%) 16 (18%)
Both lower 3 (1%) 0 (0%)
Daycare attendance, n (%)
Early daycare exposure
(≤90 days of age)
12 (5%) 0 (0%) 0.02
Late daycare exposure 99 (45%) 36 (42%) 0.61
Gender, family history of eczema, asthma, and bronchiolitis, and smoking in
the home, mother’s educational level, and type of feeding were analyzed
using Fisher's exact test. All other variables were analyzed by ANOVA;
statistical significance at P < 0.05.
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P = 0.109) (Figure 1).
The odds ratio (OR) of having at least one episode of
bronchitis/bronchiolitis, croup, nasal congestion, cough,
and diarrhea requiring medical attention was significantly
lower for the DHA/ARA versus Control group (Table 2).
The OR of increased number of episodes of bronchitis/
bronchiolitis, croup, nasal congestion, cough, and eczema,
as well as diarrhea requiring medical attention was also sig-
nificantly lower in the DHA/ARA formula group (Table 3).
In addition, the hazard ratio (HR) of time to first episode of
bronchitis/bronchiolitis, nasal congestion, cough, and diar-
rhea requiring medical attention was significantly lower in
the infants fed formula with DHA/ARA (Table 4).
Discussion
In this study, we observed that infants fed infant formula
with DHA and ARA had a lower incidence and delayed
onset of respiratory illnesses and symptoms of respiratory
illnesses, as well as diarrhea requiring medical attention,
when compared to infants who received formula without
DHA and ARA.
The previous observational study that we conducted
in Spain indicated that consumption of infant formula
with DHA and ARA was associated with a reduction in
respiratory illnesses in infants during the first year of
life, with significantly lower incidence of bronchitis/
bronchiolitis at 5, 7, and 9 months of age, and upper
respiratory infections at 1 and 12 months of age [15].
In the current study, we observed a similar, significant
reduction in the cumulative incidence of bronchitis/
bronchiolitis and croup during the first year of life. Infants
fed formula with DHA and ARA also had a lower risk,
fewer recurrent episodes, and delayed onset of bronchitis/
bronchiolitis. They were also less likely to have one or
Figure 1 Incidence of common illnesses during the first year of life. Incidence of at least one episode of illness in healthy term infants
during the first year of life, according to type of formula (with or without DHA/ARA). For each type of illness, the proportion of infants having at
least one episode during the first year of life was compared between groups using Fisher’s exact test.
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These results support our previous observation in a differ-
ent infant population and are consistent with data show-
ing that DHA and ARA impact immune function and
inflammatory responses.
The results are consistent with other reports of a lower
incidence of respiratory illnesses and symptoms among
infants who consumed infant formula with DHA and
ARA, including a retrospective review of medical re-
cords of infants that participated in two double-blind,
randomized, clinical trials in the United States [18]. The
retrospective review indicated that infants fed formula
with DHA and ARA throughout the first year of life had
a lower incidence and delayed onset of upper respiratoryTable 2 OR of having at least one episode of common
illnesses in the DHA/ARA group compared to control
OR 95% CI P-value
Respiratory illness
Bronchitis/Bronchiolitisa 0.41 (0.24, 0.70) 0.001
Croup 0.23 (0.05, 0.97) 0.045
Symptoms of
respiratory illness
Nasal Congestion 0.37 (0.20, 0.66) 0.001
Cough 0.52 (0.32, 0.86) 0.011
Other illnesses
Otitis Media 0.63 (0.36, 1.09) 0.097
Eczema 0.60 (0.34, 1.04) 0.067
Diarrhea 0.51 (0.28, 0.92) 0.026
OR obtained from multiple logistic regression analysis; aBronchitis/Bronchiolitis
was adjusted for the covariates early daycare exposure and mother’s
educational level; no other covariates reached significance for any other
illnesses; statistical significance at P < 0.05.infections and common allergic manifestations during
the first 3 years of life, compared with infants fed formula
without DHA and ARA. Similar to our current observation,
the retrospective review showed no effect of DHA/ARA on
otitis media. Overall, these findings are consistent with the
hypothesis that daily intake of LCPUFAs during the first
year of life supports the developing immune system.
Our results are also aligned with studies that have
examined the potential benefits of dietary LCPUFAs in
older children. For example, in a double-blind, randomized
clinical trial in children 18–36 months of age in the United
States primarily designed to detect changes in DHA status,
consumption of single daily serving of a cow’s milk-basedTable 3 OR of having increased number of episodes of
common illnesses in the DHA/ARA group compared
to control
OR 95% CI P-value
Respiratory illness
Bronchitis/Bronchiolitisa 0.36 (0.22, 0.59) 0.001
Croup 0.23 (0.05, 0.97) 0.045
Symptoms of
respiratory illness
Nasal Congestion 0.45 (0.29, 0.69) 0.001
Cough 0.47 (0.30, 0.74) 0.001
Other illnesses
Otitis Media 0.62 (0.36, 1.07) 0.084
Eczema 0.57 (0.33, 0.98) 0.043
Diarrhea 0.50 (0.27, 0.90) 0.021
OR obtained from ordinal model analysis; aBronchitis/Bronchiolitis was
adjusted for the covariates early daycare exposure and mother’s educational
level; no other covariates reached significance for any other illnesses; statistical
significance at P < 0.05.
Table 4 HR for shorter time to first episode of common
illnesses in the DHA/ARA group compared to control
HR 95% CI P-value
Respiratory illness
Bronchitis/Bronchiolitis 0.52 (0.36, 0.77) 0.001
Croup 0.24 (0.06, 1.00) 0.050
Symptoms of
respiratory illness
Nasal Congestion 0.72 (0.54, 0.95) 0.023
Cough 0.62 (0.45, 0.85) 0.003
Other illnesses
Otitis Media 0.67 (0.42, 1.07) 0.096
Eczema 0.70 (0.44, 1.11) 0.127
Diarrhea 0.55 (0.32, 0.93) 0.026
HR obtained from Cox proportional analysis; no covariates reached
significance for any illnesses; statistical significance at P < 0.05.
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sociated with a significantly lower incidence of respiratory
illnesses compared to the control beverage with no DHA
[19]. Additionally, a study in Thai school children found
that 9 to 12 year-old children who received milk with
fish oil for 6 months had lower incidence, fewer episodes,
and shorter duration of illnesses, including respiratory
infections [20].
LCPUFAs may influence immune cell function through
a number of mechanisms related to membrane compos-
ition, cell signalling, and gene regulation, among others [2].
Additionally, LCPUFA-derived lipid mediators appear to
have anti-inflammatory properties and hasten the resolution
of inflammation [21-23], which is consistent with clinical
studies demonstrating that inflammatory conditions may be
reduced or prevented by LCPUFAs [15,18-20,24-26].
We also found that the infants fed the DHA/ARA for-
mula had a lower risk, decreased number of episodes, de-
layed onset, and a lower incidence of diarrhea requiring
medical attention during the first year of life. Interestingly,
a recent study in India demonstrated a shorter duration of
episodes of mild gastrointestinal symptoms such as lack of
appetite or abdominal pain in children (ages 6–10) who
consumed a food supplement fortified with omega-3 fatty
acids for a period of 12 months [27]. It has been previ-
ously suggested that omega-3 fatty acids such as DHA
may reduce gastrointestinal inflammation [28], and it is
possible that the proposed anti-inflammatory properties of
DHA in the gut are reflected in our current observation
of a reduction in the incidence of more serious diarrhea
during the first year of life.
While the current results add to the understanding of
the potential health benefits of LCPUFAs in the infant
diet, our study has some important limitations. First, use
of the DHA/ARA formula could have been more prevalent
in families who were of a higher socioeconomic status.
However, differently from our previous study [15], fac-
tors such as parents’ educational level, parents’ socio-
economic status, and number of people living in thehome were recorded and included as potential covari-
ates in the statistical analysis and proved not to be dif-
ferent between the two groups (Table 1). Furthermore,
all French infants have access to free medical care, and the
spare economical resources may decrease a potential role
of the socioeconomic status in the ability of the families to
purchase infant formula.
A second inherent limitation is that the current study
was open-label and non-randomized. As such, it is possible
that the attending pediatrician may have made recommen-
dations to the parents regarding the use of infant formula
prior to study entry. Thus, the pediatrician could have inad-
vertently introduced a recruitment bias to the current
study. However, as it has been previously suggested [29],
prospective, observational studies, despite inherent limita-
tions (absence of randomization, unintentional bias, etc.),
can provide an important picture of the “real-world” utility
of a study product (in this case, infant formula with added
DHA/ARA). In spite of the observational nature of this
study, the results are consistent with and add to the existing
data of randomized, double-blind studies demonstrating an
impact of LCPUFAs, including when added to routine in-
fant formulas, on immune health outcomes.
Conclusions
Adequate intake of DHA and ARA is currently deemed
important because of potential beneficial effects on visual
acuity and brain development in infants [30], as well as
immune health [5]. Expert recommendations exist for the
amount of LCPUFA intake for pregnant and lactating
women, infants, and children [30-35], and the recommen-
dations for LCPUFAs in infant formula specify that both
DHA and ARA should be added [30,31]. Importantly, the
levels of DHA and ARA in the infant formula consumed in
this study were similar to worldwide means of LCPUFAs in
breast milk [32].
The results of this study add to the increasing evidence
that DHA and ARA added to infant formula can con-
tribute to improved respiratory health during infancy
and childhood. Additionally, dietary intake of DHA and
ARA throughout the first year of life may have a positive
effect on moderate to severe diarrhea in infants.
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